Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View
Tags:

Bristol Worldwide Rx Head Hayden Is Among Candidates In Succession Race

  • News

Executive Summary

Bristol-Myers Squibb worldwide pharmaceuticals head Donald Hayden is a 17-year company veteran with broad experience in Bristol's worldwide pharmaceutical business.

You may also be interested in...



Bristol Takes Stock: Hayden To Head U.S. Rx After Lane Departs

Bristol-Myers Squibb is turning to Exec VP Donald Hayden to restore the performance of - and confidence in - its U.S. pharmaceutical business

Bristol Takes Stock: Hayden To Head U.S. Rx After Lane Departs

Bristol-Myers Squibb is turning to Exec VP Donald Hayden to restore the performance of - and confidence in - its U.S. pharmaceutical business

Bristol President Dolan Shares CEO Heimbold's Non-Rx Background

Bristol-Myers Squibb President Peter Dolan is following the career trajectory model set by Chairman & CEO Charles Heimbold, who ascended to the top of Bristol management from a background predominantly outside the company's core pharmaceuticals business.

Table

View full table

Tags:
Latest Headlines

EU Consults On What Constitutes Personal & Commercially Confidential Data In Marketing Applications

Industry & Regulators To Align Advice on COVID-19 Vaccine Updates

Lack Of Industry Involvement In EU HTA Scoping Process Exacerbates ‘Unworkable’ Timelines

CDER, CBER Not Seeing Hiring Slowdown Despite US FDA Warnings

See All
UsernamePublicRestriction

Register

PS033142

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By